BRAF-Inhibitor-Induced Metabolic Alterations in A375 Melanoma Cells
Acquired drug tolerance has been a major challenge in cancer therapy. Recent evidence has revealed the existence of slow-cycling persister cells that survive drug treatments and give rise to multi-drug-tolerant mutants in cancer. Cells in this dynamic persister state can escape drug treatment by und...
Guardado en:
Autores principales: | Prashant Karki, Shayne Sensenbach, Vahideh Angardi, Mehmet A. Orman |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/db0b950860524ae599b0540883669795 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma
por: Hima Patel, et al.
Publicado: (2021) -
BRAF Mutation Status in Primary, Recurrent, and Metastatic Malignant Melanoma and Its Relation to Histopathological Parameters
por: Aris Spathis, et al.
Publicado: (2019) -
Dermoscopic Features as Predictors of BRAF Mutational Status and Sentinel Lymph Node Positivity in Primary Cutaneous Melanoma
por: Nika Filipović, et al.
Publicado: (2021) -
Early Experience with Dabrafenib–Trametinib Combination in Patients with BRAF-Mutated Malignant Melanoma—A Single-Center Experience
por: Sandip Ganguly, et al.
Publicado: (2021) -
Cellular Self-Digestion and Persistence in Bacteria
por: Sayed Golam Mohiuddin, et al.
Publicado: (2021)